De Domenico Carmela, Alito Angelo, Leonardi Giulia, Pironti Erica, Di Cara Marcella, Piccolo Adriana, Settimo Carmela, Quartarone Angelo, Gagliano Antonella, Cucinotta Francesca
I.R.C.C.S. Centro Neurolesi Bonino Pulejo, 98124 Messina, Italy.
Department of Biomedical, Dental Sciences and Morphological and Functional Images, University Hospital "G. Martino", 98124 Messina, Italy.
J Clin Med. 2025 Jun 5;14(11):4000. doi: 10.3390/jcm14114000.
: The co-occurrence of Attention-deficit/hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) is very common and worsens adaptive functioning. This systematic review evaluates both pharmacological and non-pharmacological interventions in this underserved population. : Registered on PROSPERO (CRD42024526157), a systematic search was conducted on PubMed, Embase, and Web of Science until 5 April 2025. The review includes (a) pilot studies and RCTs, (b) participants aged <18 years, (c) diagnoses of ASD and ADHD based on DSM-IV/V or ICD-9/10, (d) at least one group receiving any intervention, and (e) publications in English, Italian, Spanish, or German. Newcastle Ottawa Scale tools for non-randomized studies and the Cochrane Risk of Bias Tools for randomized controlled trials were used to assess studies' quality. : A total of 32 studies were included: 87.5% concerning pharmacological treatments. Specifically, methylphenidate (MPH, n = 11), atomoxetine (ATX, n = 11), guanfacina (n = 4), clonidine (n = 1), or atypical antipsychotics (n = 1) were examined. MPH and ATX were most frequently studied, with both showing positive effects in reducing ADHD core symptoms compared to placebo. ATX also reduces stereotyped behaviors and social withdrawal, although more withdrawals due to adverse events (AEs) were reported for ATX than MPH. Four studies (12.5%) examined non-pharmacological interventions, including treatment with virtual reality tools, digital platforms, educational animations, and biomedical protocols; improvements in emotion recognition, behavioral regulation, attention, and social functioning were found. : While limited data prevent definitive conclusions, MPH and ATX appear to be relatively safe and effective on hyperactivity-impulsivity symptoms, even in individuals with ASD. Evidence on non-pharmacological treatments is limited, and further studies are needed to better establish their therapeutic potential.
注意缺陷多动障碍(ADHD)与自闭症谱系障碍(ASD)共病的情况非常普遍,且会使适应性功能恶化。本系统评价评估了针对这一未得到充分治疗人群的药物和非药物干预措施。:该研究已在国际前瞻性系统评价注册库(CRD42024526157)登记,截至2025年4月5日,在PubMed、Embase和科学网进行了系统检索。该评价纳入:(a)初步研究和随机对照试验;(b)年龄小于18岁的参与者;(c)基于《精神疾病诊断与统计手册》第四版/第五版(DSM-IV/V)或国际疾病分类第九版/第十版(ICD-9/10)诊断的ASD和ADHD;(d)至少有一组接受任何干预措施;(e)以英文、意大利文、西班牙文或德文发表的文献。使用针对非随机研究的纽卡斯尔渥太华量表工具和针对随机对照试验的Cochrane偏倚风险工具来评估研究质量。:总共纳入了32项研究:87.5%涉及药物治疗。具体而言,研究了哌甲酯(MPH,n = 11)、托莫西汀(ATX,n = 11)、胍法辛(n = 4)、可乐定(n = 1)或非典型抗精神病药物(n = 1)。MPH和ATX研究得最为频繁,与安慰剂相比,两者在减轻ADHD核心症状方面均显示出积极效果。ATX还能减少刻板行为和社交退缩,不过与MPH相比,报告因不良事件(AE)导致停药的情况在ATX中更多。四项研究(12.5%)考察了非药物干预措施,包括使用虚拟现实工具、数字平台、教育动画和生物医学方案进行治疗;发现情绪识别、行为调节、注意力和社交功能有改善作用。:虽然数据有限,无法得出确定性结论,但MPH和ATX似乎对多动冲动症状相对安全有效,即使在患有ASD的个体中也是如此。非药物治疗的证据有限,需要进一步研究以更好地确定其治疗潜力。